Progressive Multiple News Today

Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a...

Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update.Dr Vitt starts by describing the...

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...

Researchers use an established murine model of cortical inflammatory demyelination to investigate the effects of vitamin D.

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...

You. this is what all came up in the hearing. did you encourage him to buy stock in this company called innate immunotherapeutiimmunoth? >> no, absolutely not. ive been involved with the immunotherapeutics in australia and new zealand for almost 15 years. im the largest shareholder and talk it all the time just like you would talk about your children. were bringing to market at some point the only drug that could treat secondary progressive multiple s multiple sclerosis, the most debilitating di...